STAT+ reported that cancer centers are grappling with persistent drug shortages that continue to disrupt patient care, with drug availability issues intersecting with how clinicians receive and administer therapy. The reporting describes operational strain and the downstream effects on treatment continuity. The update arrives alongside evidence from other studies highlighted in the same roundup regarding treatment-related biological changes, but the dominant industry signal is logistical: shortages can interfere with dosing schedules and treatment plans even when clinical protocols are well defined. For biopharma and hospitals, the coverage reinforces the need for supply reliability, contingency planning, and proactive forecasting for oncology products—especially as manufacturing lead times and regulatory constraints can limit rapid corrective action.